Drug
Fxs6837 Dose 1
Fxs6837 Dose 1: highest development phase Phase 2, developed by Shanghai Fosun Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| FXS6837 Dose 1 NCT07502638 | Phase 2 | IgAN |
Latest
No recent events.
Follow Fxs6837 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.